Home > Insider Trading > Filing (0001641172-25-002479)

Filing Details

Accession Number:: 0001641172-25-002479
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-04-02 21:01:08
Reporting Period:: 2025-03-31

Filing Date:: 2025-04-02
Accepted Time:: 2025-04-02 21:01:08
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1834105	Impact Biomedical Inc.	IBO	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1261725	Ambrose Fai Heng Chan	9 Temasek Boulevard #16-04 Suntec Tower Two Singapore U0 038989	Yes	No	Yes	No
1660984	Ltd International Alset	9 Temasek Boulevard #16-04 Suntec Tower Two Singapore U0 038989	No	No	Yes	No
1750106	Alset Inc.	4800 Montgomery Lane, Suite 210 Bethesda MD 20814	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2025-03-31	300,000	$1.03	1,253,904	No	4	S	Indirect	See footnote
Common Stock	Disposition	2025-04-01	400,000	$0.98	853,904	No	4	S	Indirect	See footnote
Common Stock	Disposition	2025-04-01	650,000	$1.45	1,910,976	No	4	S	Indirect	See footnote
Common Stock	Disposition	2025-04-01	1,176,918	$1.08	734,058	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote

Footnotes

On March 31, 2025, Alset International Limited sold 300,000 shares of the Issuer's common stock at a weighted average sale price of $1.028. This transaction was executed in multiple trades at prices ranging from $0.82 to $1.29. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
On April 1, 2025, Alset International Limited sold 400,000 shares of the Issuer's common stock at a weighted average sale price of $0.9816. This transaction was executed in multiple trades at prices ranging from $0.6938 to $1.36. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
On April 1, 2025, Alset Inc. sold 650,000 shares of the Issuer's common stock at a weighted average sale price of $1.447. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
On April 1, 2025, Alset Inc. sold 1,176,918 shares of the Issuer's common stock at a weighted average sale price of $1.08. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of an aggregate of 2,041,248 shares of common stock through the following entities: (a) 453,286 shares of common stock held by Global Biomedical Pte. Ltd. (a subsidiary of Alset International Limited); (b) 853,904 shares of common stock held by Alset International Limited; and (c) 734,058 shares of common stock held by Alset Inc.